Similarly, the dopaminergic system, highlighted in recent studies, indicates that dopamine receptors, particularly DRD2 and DRD3, are upregulated in breast cancer, potentially contributing to tumor growth and progression. This evidence concerns the gene DRD3 and breast carcinoma.